Reckitt Benckiser Group (OTCMKTS:RBGLY) Rating Lowered to “Equal Weight” at Morgan Stanley

Reckitt Benckiser Group (OTCMKTS:RBGLY) was downgraded by Morgan Stanley from an “overweight” rating to an “equal weight” rating in a report released on Monday, MarketBeat reports.

RBGLY has been the topic of several other reports. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Reckitt Benckiser Group in a report on Monday, October 27th. Barclays raised shares of Reckitt Benckiser Group from a “hold” rating to a “strong-buy” rating in a research note on Monday, December 1st. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Reckitt Benckiser Group in a report on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy”.

Reckitt Benckiser Group Trading Up 0.3%

OTCMKTS:RBGLY opened at $16.07 on Monday. Reckitt Benckiser Group has a 52 week low of $11.73 and a 52 week high of $16.30. The stock’s fifty day moving average is $15.61 and its two-hundred day moving average is $14.96. The company has a debt-to-equity ratio of 1.01, a quick ratio of 0.37 and a current ratio of 0.56.

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.